Intestinal Cancer
Also known as: Duodenal cancer, Ileal cancer, Jejunal cancer, Small intestine cancer
Methodology & AI Transparency ⓘ
Intestinal Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Your small intestine is part of your digestive system.
- 2 Real-world patient consensus: Diagnostic registry C81.6: Intestinal Cancer is managed within Cancer & Oncology (aka Duodenal cancer).
- 3 Typical cash cost range: Clinicians assessing Intestinal Cancer focus on microenvironment inflammation [Intestinal Cancer C81.6] and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Intestinal Cancer: maintaining Pathology / Molecular in Intestinal Cancer (C81.6: Genomic Staging) within Guideline-concordant surveillance (C81.6).
Ask our AI Specialists anything about Intestinal Cancer
What Is Intestinal Cancer?
Your small intestine is part of your digestive system. It is a long tube that connects your stomach to your large intestine. Intestinal cancer is rare, but eating a high-fat diet or having Crohn's disease , celiac disease, or a history of colonic polyps can increase your risk. Possible signs of small intestine cancer include: Abdominal pain Weight loss for no reason Blood in the stool A lump in the abdomen Imaging tests that create pictures of the small intestine and the area around it can help diagnose intestinal cancer and show whether it has spread. Surgery is the most common treatment. Additional options include chemotherapy, radiation therapy, or a combination.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Intestinal Cancer (C81.6) features microenvironment inflammation [Intestinal Cancer C81.6]. Cross-referenced with NIH MeSH (Ileal Neoplasms, Jejunal Neoplasms), therapeutic stabilization in cancer & oncology is verified against Complete Blood Count in Intestinal Cancer (C81.6: (ANC, Hemoglobin, Platelets)).
Common Symptoms & Clinical Signs
- • Weight loss for no reason
- • Blood in the stool
- • Presentation of Intestinal Cancer (C81.6): persistent painless lump, in Intestinal Cancer (C81.6: non-healing ulcer/mole change,)
- • Secondary Intestinal Cancer clinical sign: unintended weight loss [Intestinal Cancer C81.6]
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Intestinal Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C81.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Intestinal Cancer (C81.6: Genomic Staging) | Guideline-concordant surveillance (C81.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Intestinal Cancer (C81.6: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C81.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Intestinal Cancer (C81.6: Organ Function Panel) | Preserved renal/hepatic clearance (C81.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Intestinal Cancer
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Daily Flow Intestinal Transit (Chelidonium Majus 3c, Raphanus Sativus 3c, Rhamnus Frangula 3c) Daily Flow Intestinal Transit • RxCUI RXN-B764727008 | Over-the-Counter Clinical Monograph | 94% | $2.8700 | $ 215.14 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Intestinal Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Glasdegib plus intensive or non-intensive chemotherapy for untreated acute: What a 404-Participant Study Found The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Leukemia • 2023-10-15 • Phase III Randomized Trial | N = 404 | 93/100 | PMID 37604981 ↗ |
| What the Latest Evidence Really Says About Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese Compared to placebo, both Semaglutide and tirzepatide are associated with increased GI adverse outcomes, with most cases being mild. Annals of Saudi medicine • 2025-01-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 40189856 ↗ |
| What the Latest Evidence Really Says About Gastrointestinal side effects of metformin treatment in patients with type 2 The risk of gastrointestinal side effects such as abdominal pain, nausea and diarrhea is higher in type 2 diabetes patients treated with metformin compared to other antidiabetic drugs. Frontiers in endocrinology • 2022-01-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 36187122 ↗ |
| Can This Approach Help? Inside the Latest Research on Impact of an oral purified microbiome therapeutic on the gastrointestinal These findings on the pharmacology of VOS underscore the importance of rapidly restoring key protective functions of the microbiome in patients with recurrent CDI to achieve durable prevention of recurrence, as observed in the... Nature medicine • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41491103 ↗ |
| Faster Wake-Up After a Procedure: How a Newer Sedative Compares to Standard Anesthesia Remimazolam demonstrated a significantly higher sedation effect during upper gastrointestinal endoscopy in Japanese patients with safe and fast recovery compared with placebo. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society • 2024-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38403959 ↗ |
Intestinal Cancer Patient Community & “People Like Me” Threads
Filter Intestinal Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.